Rasha Aboelhassan, Senior Oncology Consultant at Nasser Institute Hospital, shared a post on LinkedIn:
“At ESMO Breast Cancer Congress 2026, I felt that breast cancer care is rapidly moving into a new era of precision oncology.
We are no longer speaking only about HR-positive or HER2-positive disease.
Molecular profiling and NGS are redefining breast cancer through actionable subtypes such as PI3K, BRCA, and others.
The updates presented this year brought real hope through smarter treatment selection, chemotherapy-sparing strategies, ADCs, and ctDNA-guided approaches.
For every oncologist, keeping up with these advances is becoming essential to deliver truly personalized care for our patients.”
Other articles featuring Rasha Aboelhassan on OncoDaily.